Progranulin Protein (PGRN)

📖 Wiki Page

protein1828 wordssynced 2026-04-02

Progranulin Protein (PGRN)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Progranulin (PGRN)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28799" target="_blank">P28799</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Progranulin</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>63.5 kDa (full-length); secreted fragments: 6-25 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>593 amino acids</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Secreted, Lysosomes, Cytoplasm</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Neurons, Microglia, Macrophages, Epithelial cells</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

Progranulin Protein (PGRN)

Overview

...

Progranulin Protein (PGRN)

Overview

Progranulin (PGRN) is a secreted glycoprotein encoded by the [GRN](/genes/grn) gene that functions as a crucial regulator of neuronal survival, lysosomal function, immune response, and synaptic plasticity. The protein has a molecular weight of 63.5 kDa in its full-length form and is proteolytically processed into smaller granulins (6-25 kDa) that have distinct biological activities[@baker2006]. Progranulin is localized to multiple cellular compartments including the secretory pathway, lysosomes, and cytoplasm, where it participates in diverse cellular processes[@chintapaludi2021].

Haploinsufficiency caused by [GRN](/genes/grn) mutations is one of the most common genetic causes of [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[@gtzl2020]. Additionally, GRN mutations have been implicated in [amyotrophic lateral sclerosis (ALS)](/diseases/als) and may modify [Alzheimer's disease (AD)](/diseases/alzheimers-disease) risk. The discovery that GRN mutations cause FTD through a haploinsufficiency mechanism, resulting in approximately 50% reduction in functional protein levels, has driven significant therapeutic development efforts focused on protein replacement or upregulation[@arrant2023].

Structure and Biochemistry

Primary Structure

Progranulin is a 593-amino acid secreted glycoprotein with a molecular weight of 63.5 kDa. The protein contains multiple functional domains:

| Domain | Position | Description |
|--------|----------|-------------|
| Signal peptide | 1-18 | Directs secretion via secretory pathway |
| Granulin repeats | 19-564 | 7.5 tandem repeats of ~60-80 aa each |
| Cysteine-rich regions | Between repeats | Provide structural stability |
| N-glycosylation sites | Multiple | Affect secretion and stability |

Granulin Repeats

The hallmark of progranulin is its series of granulin repeats:

P-granulin (full-length): Contains all 7.5 repeats
Granulin A-G: Individual repeats released by proteolytic cleavage
Paragranulin: Contains only the first four repeats

Each granulin repeat contains:

12 conserved cysteine residues forming disulfide bonds
Characteristic "Gliadin" fold
Protease resistance due to dense disulfide bonding

Proteolytic Processing

Progranulin is cleaved by multiple proteases:

| Protease | Cleavage Site | Result |
|----------|---------------|--------|
| Elastase | Between repeats | Granulin fragments |
| Matrix metalloproteinases (MMP-3, MMP-9) | Variable | Multiple fragments |
| Cathepsin D | Within repeats | Smaller fragments |
| ADAMTS-4 | N-terminal | Truncated forms |

The cleavage products (granulins) have distinct biological activities:

Some granulins are neurotrophic
Others may have inflammatory functions
Balance between full-length PGRN and fragments is biologically important

Post-Translational Modifications

N-linked glycosylation: Multiple sites in granulin repeats
Signal peptide cleavage: Generates mature secreted protein
Proteolytic processing: Generates active granulin fragments

Normal Physiological Function

Neuronal Survival and Development

Progranulin supports neuronal health through multiple mechanisms[@eriksen2007]:

Neurotrophic Activity:

Promotes neurite outgrowth and branching
Supports neuronal differentiation
Protects against excitotoxicity

Synaptic Function:

Regulates synaptic plasticity
Modulates neurotransmitter release
Maintains dendritic spine morphology

Anti-apoptotic Effects:

Protects neurons from various toxic insults
Reduces caspase activation
Supports mitochondrial function

Lysosomal Function

A critical function of PGRN is its role in lysosomal homeostasis[@paushter2018]:

Lysosomal Enzyme Trafficking:

Facilitates proper trafficking of cathepsin D
Regulates other lysosomal hydrolases
Maintains lysosomal pH

Autophagy Regulation:

Modulates autophagic flux
Controls cargo delivery to lysosomes
Essential for autophagosome-lysosome fusion

Lipid Metabolism:

Influences lysosomal lipid processing
Affects membrane composition
Critical for neuronal lipid homeostasis[@evers2023]

Immune Modulation

PGRN exerts immunomodulatory effects throughout the body[@zhang2019]:

Inflammatory Response:

Regulates cytokine production
Modulates immune cell activation
Can be pro- or anti-inflammatory depending on context

Microglial Function:

Critical for microglial survival
Maintains microglial morphology
Regulates phagocytic activity

Wound Healing:

Originally identified as a growth factor involved in tissue repair
Promotes angiogenesis
Supports tissue remodeling

Pathogenic Mechanisms

Haploinsufficiency

Most pathogenic [GRN](/genes/grn) mutations lead to reduced protein levels through haploinsufficiency:

| Mutation Type | Mechanism |
|--------------|------------|
| Nonsense mutations | Premature stop codons causing nonsense-mediated decay |
| Frameshift mutations | Insertions/deletions altering protein reading frame |
| Splice site mutations | Aberrant mRNA processing |
| Copy number deletions | Heterozygous deletions encompassing GRN |

The 50% reduction in PGRN levels is sufficient to cause FTD, demonstrating the critical importance of progranulin in neuronal maintenance.

Lysosomal Dysfunction

Loss of functional PGRN leads to lysosomal impairment:

Cathepsin D deficiency: Impaired processing of lysosomal substrates

Lipofuscin accumulation: Accumulation of undigested material

Autophagic stress: Impaired clearance of autophagic cargo

Lipid alterations: Lysosomal lipid accumulation

Neuronal vulnerability: Age-related neurodegeneration[@arrant2023]

TDP-43 Pathology

PGRN deficiency leads to [TDP-43](/proteins/tdp-43) (encoded by [TARDBP](/genes/tardbp)) mislocalization:

Nuclear clearance: TDP-43 translocates from nucleus to cytoplasm
Aggregation: Cytoplasmic TDP-43 inclusions form
Splicing dysregulation: Loss of nuclear TDP-43 disrupts mRNA processing
Neuronal loss: TDP-43 pathology correlates with neurodegeneration

Neuroinflammation

PGRN deficiency promotes neuroinflammation:

Increased microglial activation
Enhanced cytokine production
Altered immune responses

Role in Neurodegenerative Diseases

Frontotemporal Dementia (FTD)

GRN mutations cause TDP-43-positive FTD, representing one of the most common genetic forms:

| FTD Subtype | Percentage of GRN Cases |
|-------------|----------------------|
| Behavioral variant FTD | ~60% |
| Primary progressive aphasia | ~25% |
| Corticobasal syndrome | ~15% |

Clinical Features:

Age of onset: Typically 45-65 years
Disease duration: 5-12 years
Behavioral changes: Disinhibition, apathy, loss of empathy
Language impairment: Progressive aphasia variants
Motor symptoms: Corticobasal syndrome features

Pathology:

TDP-43 inclusions in neurons and glia
Predominantly type B (cytoplasmic) pathology
Neuronal loss and gliosis

Amyotrophic Lateral Sclerosis (ALS)

Some GRN mutations cause ALS or ALS/FTD:

Overlapping TDP-43 pathology with FTD
Combined upper and lower motor neuron signs
More rapid progression than FTD alone
May represent a disease continuum

Alzheimer's Disease

GRN may modify AD risk[@chintapaludi2021]:

Some GRN variants associated with increased AD risk
PGRN levels altered in AD brains
Potential interactions with amyloid and [tau](/proteins/tau) pathology
May influence microglial responses in AD

Other Conditions

Neuronal Ceroid Lipofuscinosis: PGRN deficiency can cause similar pathology
Age-related macular degeneration: PGRN variants associated with risk

Therapeutic Strategies

PGRN Replacement

Multiple approaches to restore PGRN levels[@nguyen2021]:

| Strategy | Approach | Status |
|----------|----------|--------|
| Recombinant PGRN | Systemically administered protein | Preclinical |
| Gene therapy | AAV-mediated GRN delivery | Preclinical/early clinical |
| Small molecule inducers | Increase GRN expression | Discovery |
| Protein stabilization | Prevent PGRN degradation | Research |

Lysosomal Enhancement

Address lysosomal dysfunction in PGRN deficiency:

Cathepsin D activators: Enhance lysosomal enzyme activity

Autophagy modulators: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors, rapamycin analogs

Lipid metabolism modifiers: Address lysosomal lipid accumulation

Gene therapy for lysosomal enzymes: Restore enzymatic function

Anti-TDP-43 Approaches

Target downstream pathology:

ASO therapy: Antisense oligonucleotides targeting TARDBP

Phosphorylation modulators: Kinase inhibitors reducing TDP-43 pathology

Aggregation inhibitors: Compounds preventing TDP-43 aggregation

Nuclear import enhancers: Promote TDP-43 nuclear localization

Immunomodulation

Microglial modulators
Anti-inflammatory approaches
Cytokine-targeted therapies

Biomarkers

Plasma/Serum PGRN

Levels: Reduced in GRN mutation carriers (heterozygotes ~50% of normal)
Use: Screening tool for genetic testing
Advantage: Non-invasive, widely available
Limitations: Not specific to FTD, overlap with other conditions[@meeter2016]

CSF Biomarkers

| Marker | Changes in GRN-FTD |
|--------|-------------------|
| Total [tau](/proteins/tau) | Elevated |
| Neurofilament light chain (NfL) | Markedly elevated |
| Cathepsin D activity | Reduced |
| PGRN | Reduced (~50%) |

Imaging

MRI for brain atrophy patterns
FDG-PET for hypometabolism
PET for neuroinflammation

Genetic Testing

Sequencing of GRN coding region
Deletion/duplication analysis
Family testing for at-risk individuals

Animal Models

Grn Knockout Mice

Phenotype: Develop lipofuscin accumulation, microgliosis
Behavior: Show subtle cognitive deficits
Aging: Accelerate age-related neurodegeneration
Therapeutic response: PGRN administration improves phenotypes[@ahmed2010]

Drosophila Models

PGRN homolog: Drosophila contains a functional ortholog (Pgranulin)
Loss-of-function: Causes neurodegeneration
Genetic modifiers: Identifies relevant pathways

Non-Human Primates

Limited studies in non-human primates
Important for translational studies

Cross-References

[GRN Gene](/genes/grn)
[TDP-43 Protein](/proteins/tdp-43)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Amyotrophic Lateral Sclerosis](/diseases/als)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
[Autophagy](/mechanisms/autophagy)
[Neuroinflammation](/mechanisms/neuroinflammation)

Key Publications

[Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia. Nature. 2006.](https://pubmed.ncbi.nlm.nih.gov/16625161/)

[Eriksen JL, Mackenzie IR. Progranulin: a new player in neurobiology. J Neurochem. 2007.](https://pubmed.ncbi.nlm.nih.gov/17727630/)

[Chintapaludi M, Baloh RH. Progranulin in the pathogenesis of AD and related dementias. Neurobiol Aging. 2021.](https://pubmed.ncbi.nlm.nih.gov/33865236/)

[Götzl JK, et al. Understanding GRN-linked FTD. Trends Neurosci. 2020.](https://pubmed.ncbi.nlm.nih.gov/32291132/)

[Minami SS, et al. Progranulin deficiency promotes neuroinflammation. J Clin Invest. 2020.](https://pubmed.ncbi.nlm.nih.gov/32271718/)

[Paushter DH, et al. The lysosomal function of progranulin. Immunobiology. 2018.](https://pubmed.ncbi.nlm.nih.gov/30268483/)

[Zhang Y, et al. Progranulin: a key player in microglial function. Nat Rev Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31073201/)

[Arrant AE, Roberson ED. Therapeutic strategies for progranulin-deficient FTD. Neuron. 2023.](https://pubmed.ncbi.nlm.nih.gov/36917592/)

[Nguyen AD, et al. A progranulin-derived therapeutic antibody restores synaptic function. Sci Transl Med. 2021.](https://pubmed.ncbi.nlm.nih.gov/33568476/)

[Evers BM, et al. Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons. Nat Commun. 2023.](https://pubmed.ncbi.nlm.nih.gov/37019960/)

External Links

UniProt: [P28799](https://www.uniprot.org/uniprot/P28799)
AlphaFold: [PGRN](https://alphafold.ebi.ac.uk/entry/P28799)
PDB: [2JYE](https://www.rcsb.org/structure/2JYE)
NCBI Gene: [GRN](https://www.ncbi.nlm.nih.gov/gene/5136)
OMIM: [607486](https://www.omim.org/entry/607486)
GeneCards: [GRN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRN)

References

[@baker2006]: Baker M, et al. [Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17](https://pubmed.ncbi.nlm.nih.gov/16625161/). Nature. 2006.

[@eriksen2007]: Eriksen JL, Mackenzie IR. [Progranulin: a new player in neurobiology](https://pubmed.ncbi.nlm.nih.gov/17727630/). J Neurochem. 2007.

[@chintapaludi2021]: Chintapaludi M, Baloh RH. [Progranulin in the pathogenesis of Alzheimer's disease and related dementias](https://pubmed.ncbi.nlm.nih.gov/33865236/). Neurobiol Aging. 2021.

[@gtzl2020]: Götzl JK, Capell A, Haass C. [Understanding GRN-linked FTD](https://pubmed.ncbi.nlm.nih.gov/32291132/). Trends Neurosci. 2020.

[@minami2020]: Minami SS, et al. [Progranulin deficiency promotes neuroinflammation and selectively increases adult hippocampal neurogenesis](https://pubmed.ncbi.nlm.nih.gov/32271718/). J Clin Invest. 2020.

[@paushter2018]: Paushter DH, et al. [The lysosomal function of progranulin](https://pubmed.ncbi.nlm.nih.gov/30268483/). Immunobiology. 2018.

[@zhang2019]: Zhang Y, Chen X, Zong J. [Progranulin: a key player in microglial function](https://pubmed.ncbi.nlm.nih.gov/31073201/). Nat Rev Neurol. 2019.

[@irwin2019]: Irwin DJ, et al. [Frontotemporal lobar degeneration: TDP-43 pathology and the role of GRN mutations](https://pubmed.ncbi.nlm.nih.gov/30848362/). Acta Neuropathol. 2019.

[@arrant2023]: Arrant AE, Roberson ED. [Therapeutic strategies for progranulin-deficient FTD](https://pubmed.ncbi.nlm.nih.gov/36917592/). Neuron. 2023.

[@nguyen2021]: Nguyen AD, et al. [A progranulin-derived therapeutic antibody restores synaptic function](https://pubmed.ncbi.nlm.nih.gov/33568476/). Sci Transl Med. 2021.

[@evers2023]: Evers BM, et al. [Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons](https://pubmed.ncbi.nlm.nih.gov/37019960/). Nat Commun. 2023.

[@meeter2016]: Meeter LH, et al. [Plasma and CSF progranulin in genetic FTD](https://pubmed.ncbi.nlm.nih.gov/26718579/). Neurology. 2016.

[@ahmed2010]: Ahmed Z, et al. [Accelerated lipofuscino genesis and microglial activation in progranulin-deficient mice](https://pubmed.ncbi.nlm.nih.gov/19501490/). Neurobiol Aging. 2010.

📖 View canonical wiki page →